Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Preferred Stock Liabilities: 2021-2022

  • Prime Medicine's Preferred Stock Liabilities rose 98.25% to $395.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $395.8 million, marking a year-over-year increase of 98.25%. This contributed to the annual value of $395.8 million for FY2021, which is 1171.20% up from last year.
  • Per Prime Medicine's latest filing, its Preferred Stock Liabilities stood at $395.8 million for Q3 2022, which was down 0.00% from $395.8 million recorded in Q4 2021.
  • Prime Medicine's Preferred Stock Liabilities' 5-year high stood at $395.8 million during Q4 2021, with a 5-year trough of $199.6 million in Q3 2021.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $395.8 million (2022), whereas its average is $330.4 million.
  • Data for Prime Medicine's Preferred Stock Liabilities shows a peak YoY surged of 98.25% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Prime Medicine's Preferred Stock Liabilities stood at $395.8 million in 2021, then soared by 98.25% to $395.8 million in 2022.
  • Its last three reported values are $395.8 million in Q3 2022, $395.8 million for Q4 2021, and $199.6 million during Q3 2021.